Earn Up to 2 Hours of CME!

DoubleTree by Hilton, San Juan P.R.

Pre-Registration is Required

No Charge Required

Program Description

This continuing education activity, participants will gain a comprehensive understanding of the pathophysiology of TED, risk factors, and the importance of early differential diagnosis. The sessions will address established and emerging monoclonal antibody therapies targeting the insulin-like growth factor-1 receptor, with a focus on translating recent clinical trial data into practical treatment strategies. Special attention will be given to recognizing and managing associated complications, including hyperglycemia and hearing loss, to ensure holistic patient care. By the end of this program, attendees will be equipped with evidence-based tools to optimize patient outcomes in TED.